Valuation: Paion AG

Market Cap 1L 2L 1L 1L 2L 1.56Cr 2L 16.3L 6L 79.55L 6L 6L 2.56Cr P/E 2021
-3.89x
P/E 2022 -53x
Enterprise Value 98.67L 1.11Cr 92.27L 84.09L 1.58Cr 106.96Cr 1.6Cr 11Cr 4.32Cr 54Cr 4.17Cr 4.08Cr 174.96Cr EV / Sales 2021
14.1x
EV / Sales 2022 1.22x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
3 months-14.81%
6 months+26.37%
Current year+248.48%
1 week 0.05
Extreme 0.046
0.05
1 month 0.05
Extreme 0.046
0.05
Current year 0.01
Extreme 0.012
0.23
1 year 0.01
Extreme 0.011
0.23
3 years 0
Extreme 0.0001
4.32
5 years 0
Extreme 0.0001
18.94
10 years 0
Extreme 0.0001
36.78
Manager TitleAgeSince
Chief Executive Officer 62 01/09/2023
Director of Finance/CFO - 01/06/2022
Director TitleAgeSince
Director/Board Member 65 01/10/2012
Director/Board Member 75 01/06/2017
Director/Board Member - 22/05/2019
Date Insider Type Main position Quantity % Market Cap. Importance
27/12/22 Buy

Director

1,121 0.0016%
12/01/21 Buy

Chief Executive Officer

8,500 0.0127%
08/06/20 Buy

Chief Executive Officer

13,158 0.0202%
Change 5-day change 1-year change 3-year change Capi.($)
+33.70%0.00%+342.31%-98.77% 4L
+4.16%+3.04%+49.37%+94.17% 7.44TCr
-0.61%+0.81%+27.25%+82.72% 5.93TCr
-2.54%-1.65%+4.86%+31.72% 4.71TCr
-3.02%-5.20%+27.94%+32.51% 4.29TCr
+0.31%+3.02%+348.95%+643.82% 4.41TCr
-1.96%-0.33%+7.04%+99.46% 4.08TCr
+3.32%+3.49%+10.10%+51.23% 3.08TCr
-3.30%+2.26%+28.80%+21.93% 2.93TCr
-4.86%-10.66%-26.27%+330.06% 2.37TCr
Average -0.85%-0.47%+82.04%+128.89% 3.92TCr
Weighted average by Cap. -0.39%-0.32%+58.44%+146.05%

Financials

2021 2022
Net sales 71.28L 80.26L 66.66L 60.75L 1.14Cr 77Cr 1.16Cr 8.06Cr 3.12Cr 39Cr 3.01Cr 2.95Cr 126.4Cr 3.32Cr 3.74Cr 3.11Cr 2.83Cr 5.33Cr 360.41Cr 5.41Cr 38Cr 15Cr 183.55Cr 14Cr 14Cr 589.55Cr
Net income -2.18Cr -2.45Cr -2.04Cr -1.86Cr -3.5Cr -236.16Cr -3.54Cr -25Cr -9.54Cr -120.27Cr -9.21Cr -9.01Cr -386.3Cr -6L -7L -5L -5L -9L -6.28Cr -9L -65.5L -25.36L -3.2Cr -24.47L -23.94L -10Cr
Net Debt 1.38Cr 1.55Cr 1.29Cr 1.17Cr 2.21Cr 149.26Cr 2.24Cr 16Cr 6.03Cr 76Cr 5.82Cr 5.69Cr 244.15Cr 97.23L 1.09Cr 90.93L 82.86L 1.56Cr 105.4Cr 1.58Cr 11Cr 4.26Cr 54Cr 4.11Cr 4.02Cr 172.41Cr
Logo Paion AG
Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
Employees
64
Date Price Change Volume
30/26/30 €0.0460 -.--% 0
01/26/01 €0.0460 0.00% 0
30/26/30 €0.0460 0.00% 0
29/26/29 €0.0460 0.00% 0
28/26/28 €0.0460 0.00% 330
  1. Stock Market
  2. Stocks
  3. PA8K Stock